Cited by 2,969Hematopoietic Stem Cell TransplantationInflammatory Biomarkers in Disease PrognosisRenal Transplantation Outcomes and Treatments

The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Open access

Sorror, Mohamed L., Maris, Michael B., Storb, Rainer, Baron, Frederic, Sandmaier, Brenda M., Maloney, David G., Storer, Barry·2005·Blood

DOI 10.1182/blood-2005-05-2004PMC PMC1895304

Open this paper in CoChat — free account Open PDF

Abstract

We previously reported that the Charlson Comorbidity Index (CCI) was useful for predicting outcomes in patients undergoing allogeneic hematopoietic cell transplantation (HCT). However, the sample size of patients with scores of 1 or more, captured by the CCI, did not exceed 35%. Further, some comorbidities were rarely found among patients who underwent HCT. Therefore, the current study was designed to (1) better define previously identified comorbidities using pretransplant laboratory data, (2) investigate additional HCT-related comorbidities, and (3) establish comorbidity scores that were suited for HCT. Data were collected from 1055 patients, and then randomly divided into training and validation sets. Weights were assigned to individual comorbidities according to their prognostic significance in Cox proportional hazard models. The new index was then validated. The new index proved to be more sensitive than the CCI since it captured 62% of patients with scores more than 0 compared with 12%, respectively. Further, the new index showed better survival prediction than the CCI (likelihood ratio of 23.7 versus 7.1 and c statistics of 0.661 versus 0.561, respectively, P < .001). In conclusion, the new simple index provided valid and reliable scoring of pretransplant comorbidities that predicted nonrelapse mortality and survival. This index will be useful for clinical trials and patient counseling before HCT. (Blood. 2005;106: 2912-2919)

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1182/blood-2005-05-2004

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452
The Statistical Analysis of Failure Time Data.
Aitkin, M. A., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,875
Validation of a combined comorbidity index
Charlson, M., Szatrowski, T. P., Peterson, J., & Gold, J. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90129-5 · Cited by 6,587
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Regression modelling strategies for improved prognostic prediction
Harrell, F. E., Lee, K. L., Califf, R. M., Pryor, D. B., & Rosati, R. A. (1984) · Statistics in Medicine · doi:10.1002/sim.4780030207 · Cited by 1,804
Presentation adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives
Romano, P. S., Roos, L. L., & Jollis, J. G. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90103-8 · Cited by 1,717
The pre-therapeutic classification of co-morbidity in chronic disease
Feinstein, A. R. (1970) · Journal of Chronic Diseases · doi:10.1016/0021-9681(70)90054-8 · Cited by 1,544
Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia
Storb, R. F., Deeg, H. J., Whitehead, J., Appelbaum, F. R., Beatty, P. G., Bensinger, W., Buckner, C. D., Clift, R. A., Doney, K., Farewell, V. T., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603203141201 · Cited by 1,411
Self-citation
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
McSweeney, P. A., Niederwieser, D. W., Shizuru, J. A., Sandmaier, B. M., Molina, A. J., Maloney, D. G., Chauncey, T. R., Gooley, T. A., Hegenbart, U., Nash, R. A., et al. (2001) · Blood · doi:10.1182/blood.v97.11.3390 · Cited by 1,386
Self-citation

Show all 62 references

Research works printed but not linked: 1

Lubke T, Monig SP, Schneider PM, Holscher AH, Bollschweiler E. Does Charlson-comorbidity index correlate with short-term outcome in patients with gastric cancer? [German]. Zentralblatt für Chirurgie.2003;128: 970-976.

Sorted by citations

Items 401–500 of 1,002

Vancomycin-Resistant Enterococcus Colonization and Bacteremia and Hematopoietic Stem Cell Transplantation Outcomes
Ford, C. D., Gazdik, M. A., Lopansri, B. K., Webb, B. J., Mitchell, B., Coombs, J., Hoda, D., & Petersen, F. B. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.11.017 · Cited by 54
Graft-versus-Host disease Prophylaxis with Everolimus and Tacrolimus Is Associated with a High Incidence of Sinusoidal Obstruction Syndrome and Microangiopathy: Results of the EVTAC Trial
Platzbecker, U., Bonin, M. V., Goekkurt, E., Radke, J., Binder, M., Kiani, A., Stoehlmacher, J., Schetelig, J., Thiede, C., Ehninger, G., et al. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.11.004 · Cited by 54
Reduced-Intensity Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: A Report from the SFGM-TC
Chevallier, P., Szydlo, R., Blaise, D., Tabrizi, R., Michallet, M., Uzunov, M., Fegueux, N., Guilhot, F., Lapusan, S., Gratecos, N., et al. (2011) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.07.013 · Cited by 53
Multi‐centre validation of the prognostic value of the haematopoietic cell transplantation‐ specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation
Elsawy, M., Storer, B. E., Pulsipher, M. A., Maziarz, R. T., Bhatia, R., Maris, M. B., Syrjala, K. L., Martin, P. J., Maloney, D. G., Sandmaier, B. M., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13476 · Cited by 53
Self-citation
The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia
Fredly, H., Ersvær, E., Kittang, A. O., Tsykunova, G., Gjertsen, B. T., & Bruserud, Ø. (2013) · Clinical Epigenetics · doi:10.1186/1868-7083-5-13 · Cited by 53
Critically ill allogeneic hematopoietic stem cell transplantation patients in the intensive care unit: reappraisal of actual prognosis
Saillard, C., Blaise, D., & Mokart, D. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.72 · Cited by 53
Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) in Single and Multiple Institutions: Limitations and Inferences
Sorror, M. L., Storer, B. E., & Storb, R. F. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.02.007 · Cited by 53
Self-citation
Comparison of Outcomes after Peripheral Blood Haploidentical versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia: A Retrospective Single-Center Review
Rashidi, A., DiPersio, J. F., Westervelt, P., Vij, R., Schroeder, M. A., Cashen, A. F., Fehniger, T. A., & Romee, R. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.05.010 · Cited by 52
Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity
Shimoni, A., Shem‐Tov, N., Volchek, Y., Danylesko, I., Yerushalmi, R., & Nagler, A. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.4 · Cited by 52
Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients
van der Helm, L. H., Scheepers, E. R. M., Veeger, N. J. G. M., Daenen, S. M. G. J., Mulder, A. B., van den Berg, E., Vellenga, E., & Huls, G. A. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-29 · Cited by 52
New insights into transfusion-related iron toxicity: Implications for the oncologist
Porter, J. B., de Witte, T., Cappellini, M. D., & Gattermann, N. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.11.017 · Cited by 55
How I treat acute myeloid leukemia presenting with preexisting comorbidities
Ofran, Y., Tallman, M. S., & Rowe, J. M. (2016) · Blood · doi:10.1182/blood-2016-01-635060 · Cited by 52
Acute kidney injury in HCT: an update
Lopes, J. A., Jorge, S., & Neves, M. R. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.357 · Cited by 52
Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma
Castagna, L., Bramanti, S., Devillier, R., Sarina, B., Crocchiolo, R., Fürst, S., Cheikh, J. E., Granata, A., Faucher, C., Harbi, S., et al. (2017) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.348 · Cited by 52
Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome
Slade, M., DiPersio, J. F., Westervelt, P., Vij, R., Schroeder, M. A., & Romee, R. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.06.019 · Cited by 52
Functional Status as Measured by Geriatric Assessment Predicts Inferior Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients
Huang, L., Sheng, Y., Andreadis, C. B., Logan, A. C., Mannis, G. N., Smith, C. C., Gaensler, K. M. L., Martin, T. G., Damon, L. E., Steinman, M. A., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.08.022 · Cited by 53
Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies
Sanz, J., Montoro, J., Solano, C., Valcárcel, D., Sampol, A., Ferra, C. M., Parody, R., Lorenzo, I., Montesinos, P., Ortí, G., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.10.014 · Cited by 52
Prognostic factors and long‐term follow‐up of basiliximab for steroid‐refractory acute graft‐versus‐host disease : Updated experience from a large‐scale study
Liu, S., Zhang, X., Xu, L., Wang, Y., Yan, C., Chen, H., Chen, Y., Han, W., Wang, F., Wang, J., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.25839 · Cited by 52
High progression-free survival after intermediate intensity double unit cord blood transplantation in adults
Barker, J. N., Devlin, S. M., Naputo, K. A., Skinner, K., Maloy, M., Flynn, L., Anagnostou, T., Avecilla, S. T., Scaradavou, A., Cho, C., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020003371 · Cited by 52
Rationale and Design of the Chronic GVHD Cohort Study: Improving Outcomes Assessment in Chronic GVHD
(2011) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.05.007 · Cited by 52
Allogeneic Stem Cell Transplantation for Myelofibrosis in 2012
McLornan, D. P., Mead, A. J., Jackson, G. H., & Harrison, C. N. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09107.x · Cited by 51
Increased Infections and Delayed CD4+ T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation
Khimani, F., Ranspach, P., Elmariah, H., Kim, J., Whiting, J., Nishihori, T., Locke, F. L., Perez, A. P., Dean, E. A., Mishra, A., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.07.023 · Cited by 51
FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML
Song, Y., Magenau, J. M., Li, Y., Braun, T. W., Chang, L., Bixby, D. L., Hanauer, D. A., Chughtai, K. A., Gatza, E., Couriel, D., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.170 · Cited by 51
Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study
Schleuning, M., Judith, D., Jedlickova, Z., Stübig, T., Heshmat, M., Baurmann, H., & Schwerdtfeger, R. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.377 · Cited by 51
Comparable outcomes between younger (⩽40 years) and older (>40 years) adult patients with severe aplastic anemia after HLA-matched sibling stem cell transplantation using fludarabine-based conditioning
Shin, S., Jeon, Y., Yoon, J.-H., Yahng, S., Lee, S. E., Cho, B. S., Eom, K., Kim, Y. J., Lee, S.-M., Min, C., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.171 · Cited by 51
Fitness in the elderly: how to make decisions regarding acute myeloid leukemia induction
Rao, A. V. (2016) · Hematology · doi:10.1182/asheducation-2016.1.339 · Cited by 51
Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group
Pleyer, L., Döhner, H., Dombret, H., Seymour, J. F., Schuh, A. C., Beach, C. L., Swern, A. S., Burgstaller, S., Stauder, R., Girschikofsky, M., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020415 · Cited by 51
Anthracycline-related cardiotoxicity in older patients with acute myeloid leukemia: a Young SIOG review paper
Neuendorff, N. R., Loh, K. P., Mims, A. S., Christofyllakis, K., Soo, W. K., Bölükbasi, B., Algar, C. O., Hundley, W. G., & Klepin, H. D. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000955 · Cited by 53
Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT
Mehta, R. S., Holtan, S. G., Wang, T., Hemmer, M., Spellman, S. R., Arora, M., Couriel, D. R., Alousi, A. M., Pidala, J., Abdel‐Azim, H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00396 · Cited by 51
THE INTERNATIONAL PROGNOSTIC INDEX IS ASSOCIATED WITH OUTCOMES IN DIFFUSE LARGE B CELL LYMPHOMA AFTER CAR T CELL THERAPY
Garcia-recio, M., Wudhikarn, K., Pennisi, M., Alonso-Trillo, R., Flynn, J., Shouval, R., Afuye, A., Silverberg, M. L., Batlevi, C., Dahi, P., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2020.10.022 · Cited by 46
The clinical and functional effects of TERT variants in myelodysplastic syndrome
Reilly, C. R., Myllymäki, M., Redd, R. A., Padmanaban, S., Karunakaran, D., Tesmer, V. M., Tsai, F. D., Gibson, C. J., Rana, H. Q., Zhong, L., et al. (2021) · Blood · doi:10.1182/blood.2021011075 · Cited by 51
Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT
Polverelli, N., Hernández‐Boluda, J. C., Czerw, T., Barbui, T., D’Adda, M., Deeg, H. J., Ditschkowski, M., Harrison, C. N., Kröger, N. M., Mesa, R. A., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00330-1 · Cited by 52
Biologic vs physiologic age in the transplant candidate
Artz, A. S. (2016) · Hematology · doi:10.1182/asheducation-2016.1.99 · Cited by 50
Guideline for the management of mantle cell lymphoma
McKay, P., Leach, M., Jackson, B., Robinson, S. P., & Rule, S. A. (2018) · British Journal of Haematology · doi:10.1111/bjh.15283 · Cited by 50
Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia
Lund, T. C., Ahn, K. W., Tecca, H. R., Hilgers, M. V., Abdel‐Azim, H., Abraham, A., Díaz, M. Á., Badawy, S. M., Broglie, L. A., Brown, V. I., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.09.016 · Cited by 50
Pre-hematopoietic cell transplant Ruxolitinib in patients with primary and secondary myelofibrosis
Salit, R. B., Scott, B. L., Stevens, E. A., Baker, K. K., Gooley, T. A., & Deeg, H. J. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0523-3 · Cited by 50
Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation
Hernández‐Boluda, J. C., Pereira, A., Kröger, N. M., Beelen, D. W., Robin, M., Bornhäuser, M., Angelucci, E., Vı́tek, A., Blau, I. W., Niittyvuopio, R., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0815-z · Cited by 50
Chronic GVHD induced GVL effect after unmanipulated haploidentical hematopoietic SCT for AML and myelodysplastic syndrome
Mo, X.-D., Xu, L.-P., Zhang, X.-H., Liu, D.-H., Wang, Y., Chen, H., Yan, C.-H., Chen, Y.-H., Han, W., Wang, F.-R., et al. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.223 · Cited by 49
Iron Overload in Patients Undergoing Hematopoietic Stem Cell Transplantation
Pullarkat, V. A. (2010) · Advances in Hematology · doi:10.1155/2010/345756 · Cited by 51
Feasibility of Frequent Patient-Reported Outcome Surveillance in Patients Undergoing Hematopoietic Cell Transplantation
Wood, W. A., Deal, A. M., Abernethy, A. P., Basch, E., Battaglini, C. L., Kim, Y. H., Whitley, J., Shatten, C., Serody, J. S., Shea, T. C., et al. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.11.014 · Cited by 49
Vancomycin‐resistant E nterococcus colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia
Hefazi, M., Damlaj, M., Alkhateeb, H. B., Partain, D. K., Patel, R., Razonable, R. R., Gastineau, D. A., Al‐Kali, A., Hashmi, S. K., Hogan, W. J., et al. (2016) · Transplant Infectious Disease · doi:10.1111/tid.12612 · Cited by 49
Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma
Qazilbash, M., Saliba, R. M., Hosing, C. M., Mendoza, F. L., Qureshi, S. R., Weber, D. M., Wang, M., Flosser, T., Couriel, D. R., Lima, M. J. G. D., et al. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705580 · Cited by 48
Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma
Davis, J. A., Dima, D., Ahmed, N., DeJarnette, S., McGuirk, J. P., Jia, X., Raza, S., Khouri, J., Valent, J. N., Anwer, F., et al. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.12.015 · Cited by 50
Cardiovascular Management of Patients Undergoing Hematopoietic Stem Cell Transplantation: From Pretransplantation to Survivorship: A Scientific Statement From the American Heart Association
Hayek, S. S., Zaha, V. G., Bogle, C., Deswal, A. M., Langston, A. A., Rotz, S. J., Vasbinder, A. L., Yang, E. H., & Okwuosa, T. M. (2024) · Circulation · doi:10.1161/cir.0000000000001220 · Cited by 54
Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T‐cell and natural killer‐cell lymphomas
Shustov, A. R., Gooley, T. A., Sandmaier, B. M., Shizuru, J. A., Sorror, M. L., Sahebi, F., McSweeney, P. A., Niederwieser, D. W., Bruno, B., Storb, R. F., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08210.x · Cited by 48
Self-citation
Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas
Castagna, L., Bramanti, S., Fürst, S., Giordano, L., Crocchiolo, R., Sarina, B., Mauro, E. D., Morabito, L., Bouabdallah, R., Coso, D., et al. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.197 · Cited by 48
Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation Score Allows a Better Stratification of High-Risk Patients Undergoing Reduced-Toxicity Allogeneic Hematopoietic Cell Transplantation
Barba, P., Martino, R., Pérez‐Simón, J. A., Fernández‐Avilés, F., Castillo, N., Piñana, J. L., López‐Anglada, L., Rovira, M., Bosch, F., Carreras, E., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.10.011 · Cited by 48
Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation
Tischer, J., Engel, N., Fritsch, S. M., Prevalšek, D., Hubmann, M., Schulz, C. U., Zoellner, A., Bücklein, V., Lippl, S., Reibke, R., et al. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.83 · Cited by 48
Prognostic Factor and Quality of Life Analysis in 160 Patients Aged ≥60 Years with Hematologic Neoplasias Treated with Allogeneic Hematopoietic Cell Transplantation
Deschler-Baier, B., Binek, K., Ihorst, G., Marks, R., Wäsch, R., Bertz, H., & Finke, J. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.02.004 · Cited by 48
Factors Predicting Graft-versus-Host Disease–Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center
Solh, M., Zhang, X., Connor, K., Brown, S. L., Solomon, S. R., Morris, L. E., Holland, H. K., & Bashey, A. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.04.006 · Cited by 48
Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?
Robinson, T. M., Fuchs, E. J., Zhang, M., Martin, A. S., Labopin, M., Keesler, D. A., Blaise, D., Bashey, A., Bourhis, J.-H., Ciceri, F., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018018291 · Cited by 48
The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation
Fein, J. A., Shimoni, A., Labopin, M., Shem‐Tov, N., Yerushalmi, R., Magen, H., Furie, N., Kopel, E., Danylesko, I., Nagler, A., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0185-y · Cited by 48
Impact of Body Mass Index on Outcomes of Hematopoietic Stem Cell Transplantation in Adults
Doney, K., McMillen, K. K., Buono, L., Deeg, H. J., & Gooley, T. A. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.10.006 · Cited by 48
Pulmonary Complications in Pediatric and Adolescent Patients Following Allogeneic Hematopoietic Cell Transplantation
Broglie, L. A., Fretham, C., Al-Seraihy, A. S., George, B., Kurtzberg, J., Loren, A. W., MacMillan, M. L., Martinez, C. A., Davies, S. M., & Pasquini, M. C. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.06.004 · Cited by 48
Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53- mutated MDS/AML
Nawas, M. T., & Kosuri, S. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010417 · Cited by 49
Outcome of BEAM‐autologous and BEAM‐alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma
Ingram, W. A., Devereux, S., Das-Gupta, E. P., Russell, N. H., Haynes, A., Byrne, J., Shaw, B. E., McMillan, A., González, J. A., Ho, A. Y. L., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07067.x · Cited by 47
The hematopoietic cell transplantation comorbidity index is a predictor of early death and survival in adult acute myeloid leukemia patients
Savić, A., Kvrgic, V., Rajić, N., Urošević, I., Kovačević, D., Perčić, I., & Popović, S. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.11.021 · Cited by 47
Controversies surrounding iron chelation therapy for MDS
Leitch, H. A. (2010) · Blood Reviews · doi:10.1016/j.blre.2010.09.003 · Cited by 46
Preparative Regimen Dosing for Hematopoietic Stem Cell Transplantation in Patients with Chronic Kidney Disease: Analysis of the Literature and Recommendations
Bodge, M. N., Reddy, S., Thompson, M. S., & Savani, B. N. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.02.013 · Cited by 47
What are the most important donor and recipient factors affecting the outcome of related and unrelated allogeneic transplantation?
Anasetti, C. (2008) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2008.10.002 · Cited by 47
Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older
Kawamura, K., Kako, S., Mizuta, S., Ishiyama, K., Aoki, J., Yano, S., Fukuda, T., Uchida, N., Ozawa, Y., Eto, T., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.09.003 · Cited by 47
Clinical impact of colonization with multidrug‐resistant organisms on outcome after allogeneic stem cell transplantation in patients with acute myeloid leukemia
Scheich, S., Lindner, S., Koenig, R., Reinheimer, C., Wichelhaus, T. A., Hogardt, M., Besier, S. M., Kempf, V. A. J., Kessel, J. M., Martin, H., et al. (2017) · Cancer · doi:10.1002/cncr.31045 · Cited by 47
Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide
McCurdy, S. R., Kanakry, C. G., Tsai, H., Gojo, I., Smith, B. D., Gladstone, D. E., Bolaños‐Meade, J., Borrello, I., Matsui, W. H., Swinnen, L. J., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.12.767 · Cited by 47
Transplant center characteristics and survival after allogeneic hematopoietic cell transplantation in adults
Majhail, N. S., Mau, L., Chitphakdithai, P., Denzen, E. M., Joffe, S., Lee, S. J., LeMaistre, C. F., Loberiza, F. R., Parsons, S. K., Repaczki-Jones, R., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0748-1 · Cited by 47
Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy
Winters, A. C., Bosma, G., Abbott, D., Minhajuddin, M., Jordan, C. T., Pollyea, D. A., & Gutman, J. A. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.07.022 · Cited by 46
EASIX-1year and late mortality after allogeneic stem cell transplantation
Kordelas, L., Terzer, T., Gooley, T., Davis, C., Sandmaier, B. M., Sorror, M. L., Penack, O., Schaeper, N. D. E., Blau, I. W., Beelen, D. W., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008617 · Cited by 46
Self-citation
Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial
Brissot, É., Labopin, M., Labussière, H., Fossard, G., Chevallier, P., Guillaume, T., Yakoub‐Agha, I., Srour, M., Bulabois, C., Huynh, A., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-00990-3 · Cited by 46
Risk Assessment for Acute Kidney Injury after Allogeneic Hematopoietic Stem Cell Transplantation Based on Acute Kidney Injury Network Criteria
Mori, J., Ohashi, K., Yamaguchi, T., Ando, M., Hirashima, Y., Kobayashi, T., Kakihana, K., & Sakamaki, H. (2012) · Internal Medicine · doi:10.2169/internalmedicine.51.7418 · Cited by 46
Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML
Lim, Z. Y., Ingram, W. A., Brand, R., Ho, A. Y. L., Kenyon, M., Devereux, S., Marsh, J. C. W., Mufti, G. J., & Pagliuca, A. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.236 · Cited by 46
Frequency of Allogeneic Hematopoietic Cell Transplantation Among Patients With High- or Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission
Mawad, R., Gooley, T. A., Sandhu, V. K., Lionberger, J. M., Scott, B. L., Sandmaier, B. M., O’Donnell, P. V., Becker, P. S., Petersdorf, S. H., Dorcy, K. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.2567 · Cited by 46
Self-citation
Reevaluation of the Pretransplant Assessment of Mortality Score after Allogeneic Hematopoietic Transplantation
Au, B. K. C., Gooley, T. A., Armand, P. A., Fang, M., Madtes, D. K., Sorror, M. L., Boeckh, M. J., Gibson, C. J., Deeg, H. J., Storb, R. F., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.01.011 · Cited by 46
Self-citation
Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes
Efficace, F., Gaïdano, G., Sprangers, M. A. G., Cottone, F., Breccia, M., Voso, M. T., Caocci, G., Stauder, R., Tucci, A. A. D., Sanpaolo, G., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt557 · Cited by 46
Hematopoietic Stem Cell Transplantation for MDS
Bartenstein, M., & Deeg, H. J. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.02.003 · Cited by 46
Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens
Saber, W., & Horowitz, M. M. (2016) · Hematology · doi:10.1182/asheducation-2016.1.478 · Cited by 46
Cardiomyopathy in patients after posttransplant cyclophosphamide–based hematopoietic cell transplantation
Lin, C.-J., Vader, J. M., Slade, M., DiPersio, J. F., Westervelt, P., & Romee, R. (2017) · Cancer · doi:10.1002/cncr.30534 · Cited by 46
Acute Kidney Injury in the Modern Era of Allogeneic Hematopoietic Stem Cell Transplantation
Abramson, M. H., Gutgarts, V., Zheng, J., Maloy, M., Ruiz, J. D., Scordo, M., Jaimes, E. A., & Sathick, I. J. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.19801220 · Cited by 48
Cytokine release syndrome after haploidentical hematopoietic cell transplantation: an international multicenter analysis
Abboud, R., Wan, F., Mariotti, J., Arango, M., Castagna, L., Romee, R., Hamadani, M., & Chhabra, S. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01403-w · Cited by 49
Does the Hematopoietic Cell Transplantation Specific Comorbidity Index (HCT-CI) Predict Transplantation Outcomes? A Prospective Multicenter Validation Study of the Kanto Study Group for Cell Therapy
Nakaya, A., Mori, T., Tanaka, M., Tomita, N., Nakaseko, C., Yano, S., Fujisawa, S., Sakamaki, H., Aotsuka, N., Yokota, A., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.06.005 · Cited by 45
Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation
Boehm, A., Sperr, W. R., Leitner, G. C., Worel, N., Oehler, L., Jaeger, E., Mitterbauer, M., Haas, O. A., Valent, P., Kalhs, P., et al. (2008) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2008.02041.x · Cited by 45
The skinny on obesity and plasma cell myeloma: a review of the literature
Carson, K. R., Bates, M. L., & Tomasson, M. H. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.71 · Cited by 46
High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell–Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia
Ponce, D. M., Hilden, P. D., Devlin, S. M., Maloy, M., Lubin, M. N., Castro-Malaspina, H. R., Dahi, P. B., Hsu, K. C., Jakubowski, A. A., Kernan, N. A., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.07.029 · Cited by 45
Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia: a survey on behalf of Eurocord and CLWP of EBMT
Robin, M., Sanz, G. F., Ionescu, I., Rio, B., Sîrvent, A., Renaud, M., Carreras, E., Milpied, N. J., Mohty, M., Beguin, Y. P., et al. (2010) · Leukemia · doi:10.1038/leu.2010.219 · Cited by 45
High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age
Hosing, C. M., Saliba, R. M., Okoroji, G., Popat, U., Couriel, D. R., Ali, T., Silva, L. D. P., Kebriaei, P., Alousi, A. M., Lima, M. J. G. D., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm608 · Cited by 45
A systematic review of prognostic factors at the end of life for people with a hematological malignancy
Button, E., Chan, R. J., Chambers, S., Butler, J., & Yates, P. M. (2017) · BMC Cancer · doi:10.1186/s12885-017-3207-7 · Cited by 45
Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis
Iqbal, M., Reljic, T., Ayala, E., Sher, T., Murthy, H. S., Roy, V., Foran, J. M., Tun, H. W., Kumar, A., & Kharfan‐Dabaja, M. A. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.08.019 · Cited by 46
Pilot randomized trial of an electronic symptom monitoring and reporting intervention for hospitalized adults undergoing hematopoietic stem cell transplantation
Bryant, A. L., Coffman, E. M., Phillips, B., Tan, X. M., Bullard, E., Hirschey, R., Bradley, J., Bennett, A. V., Stover, A. M., Song, L., et al. (2019) · Supportive Care in Cancer · doi:10.1007/s00520-019-04932-9 · Cited by 45
Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation
Rotz, S. J., Ryan, T. D., & Hayek, S. S. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02344-9 · Cited by 47
Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: Results of a Phase II Randomized Trial
Qazilbash, M. H., Saliba, R. M., Nieto, Y. L., Parikh, G. C., Pelosini, M., Khan, F. B., Jones, R. B., Hosing, C. M., Mendoza, F. L., Weber, D. M., et al. (2008) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.09.019 · Cited by 45
Factors associated with Self-reported Physical and Mental Health after Hematopoietic Cell Transplantation
Wingard, J. R., Huang, I.-C., Sobocinski, K., Andrykowski, M., Cella, D., Rizzo, J., Brady, M., Horowitz, M., & Bishop, M. (2010) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2010.05.017 · Cited by 45
Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation
Mayor, N. P., Wang, T., Lee, S. J., Kuxhausen, M., Vierra‐Green, C., Barker, D. J., Auletta, J. J., Bhatt, V. R., Gadalla, S. M., Gragert, L. A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03643 · Cited by 44
Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase
Cherington, C. C., Slack, J. L., Leis, J. F., Adams, R. H., Reeder, C. B., Mikhael, J. R., Camoriano, J. K., Noël, P., Fauble, V. D. S., Betcher, J. A., et al. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.04.021 · Cited by 44
Prognostic Classification and Risk Assessment in Myelodysplastic Syndromes
Cazzola, M., & Malcovati, L. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.02.005 · Cited by 46
Symptom burden after autologous stem cell transplantation for multiple myeloma
Campagnaro, E. L., Saliba, R. M., Giralt, S., Roden, L., Mendoza, F. L., Aleman, A., Cleeland, C. S., Weber, D., Brown, J. O., & Anderson, K. O. (2008) · Cancer · doi:10.1002/cncr.23299 · Cited by 44
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Low Left Ventricular Ejection Fraction
Qazilbash, M. H., Amjad, A. I., Qureshi, S. R., Qureshi, S., Saliba, R. M., Khan, Z. U., Hosing, C. M., Giralt, S. A., de Lima, M. J., Popat, U., et al. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.06.001 · Cited by 44
Baseline body mass index among children and adults undergoing allogeneic hematopoietic cell transplantation: clinical characteristics and outcomes
Gleimer, M., Li, Y., Chang, L., Paczesny, S., Hanauer, D. A., Frame, D. G., Byersdorfer, C. A., Reddy, P., Braun, T., & Choi, S. W. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.280 · Cited by 44
Anti-HLA antibodies other than against HLA-A, -B, -DRB1 adversely affect engraftment and nonrelapse mortality in HLA-mismatched single cord blood transplantation: possible implications of unrecognized donor-specific antibodies.
Yamamoto, H., Uchida, N., Matsuno, N., Ota, H., Kageyama, K., Wada, S., Kaji, D., Nishida, A., Ishiwata, K., Takagi, S., et al. (2014) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2014.06.024 · Cited by 37
Early-onset acute kidney injury is a poor prognostic sign for allogeneic SCT recipients
Shingai, N., Morito, T., Najima, Y., Kobayashi, T., Doki, N., Kakihana, K., Ohashi, K., & Ando, M. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.188 · Cited by 44
Ex Vivo CD34+–Selected T Cell–Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response
Barba, P., Hilden, P. D., Devlin, S. M., Maloy, M., Dierov, D., Nieves, J., Garrett, M. D., Sogani, J., Cho, C., Barker, J. N., et al. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.12.633 · Cited by 44
Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation
Kekre, N. K., Kim, H. T., Ho, V. T., Cutler, C. S., Armand, P. A., Nikiforow, S., Alyea, E. P., Soiffer, R. J., Antin, J. H., Connors, J. M., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.164012 · Cited by 44
Frailty: the missing piece of the pre- hematopoietic cell transplantation assessment?
Hegde, A. M., & Murthy, H. S. (2017) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.192 · Cited by 44

Authors: Sorror, M. L., Maris, M. B., Storb, R., Baron, F., Sandmaier, B. M., Maloney, D. G., & Storer, B.
Affiliations: University of Washington (US)
From the Fred Hutchinson Cancer Research Center, Seattle, WA; and the University of Washington, Seattle, WA.
ORCID: Sorror, Mohamed L.
Storb, Rainer
Sandmaier, Brenda M.
Maloney, David G.
Storer, Barry
Venue: Blood
Publisher: American Society of Hematology
Published: 2005-10-15
Volume: 106
Issue: 8
Pages: 2912-2919
ISSN: 0006-4971 (ISSN-L)
1528-0020
DOI: 10.1182/blood-2005-05-2004
PMC: PMC1895304
OpenAlex: W2128812336
Cited by: 2,969
References: 62
Citations by year: 2026: 139 · 2025: 208 · 2024: 223 · 2023: 213 · 2022: 192 · 2021: 246 · 2020: 209 · 2019: 171 · 2018: 173 · 2017: 174 · 2016: 144 · 2015: 145 · 2014: 134 · 2013: 112 · 2012: 86
FWCI: 25.46
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Blood (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
ORBi (University of Liège) (submittedVersion, other-oa)
Funders: Fred Hutchinson Cancer Research Center
University of Washington
National Heart, Lung, and Blood Institute (HL-36444, P01HL036444)
National Cancer Institute (CA 49605, CA18029, CA 15704+, K23CA092058, CA 78902, CA92058, P01CA049605, P30CA015704, P01CA018029, P01CA078902)
Topics: Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
Keywords: hematopoietic stem cell transplantation, allogeneic transplantation, comorbidity index, Charlson Comorbidity Index, risk assessment, non-relapse mortality, survival prediction, prognostic scoring
MeSH terms: Contraindications, Adolescent, Adult, Aged, Cause of Death, Child, Child, Preschool, Female, Humans, Infant, Male, Middle Aged, Prognosis, Transplantation, Homologous, Reproducibility of Results, Comorbidity, Survival Rate, Proportional Hazards Models, Treatment Outcome, Risk Assessment, Stem Cell Transplantation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks